1. Clcn7F318L/+ as a new mouse model of Albers-Schönberg disease
- Author
-
Samantha Lessard, H. R. Noonan, Dorothy Hu, Joana Caetano-Lopes, Matthew L. Warman, Daniel J. Horan, Kyung Eun Lim, Alexander G. Robling, K. Espinoza, Roland Baron, Steven Hann, and Kyung Shin Kang
- Subjects
0301 basic medicine ,Histology ,biology ,Physiology ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Osteopetrosis ,Dominant-Negative Mutation ,medicine.disease ,Molecular biology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Mutant protein ,Osteoclast ,Immunology ,Knockout mouse ,medicine ,biology.protein ,Autosomal dominant osteopetrosis type 2 ,Interferon gamma ,CLCN7 ,medicine.drug - Abstract
Dominant negative mutations in CLCN7, which encodes a homodimeric chloride channel needed for matrix acidification by osteoclasts, cause Albers-Schonberg disease (also known as autosomal dominant osteopetrosis type 2). More than 25 different CLCN7 mutations have been identified in patients affected with Albers-Schonberg disease, but only one mutation (Clcn7G213R) has been introduced in mice to create an animal model of this disease. Here we describe a mouse with a different osteopetrosis-causing mutation (Clcn7F318L). Compared to Clcn7+/+ mice, 12-week-old Clcn7F318L/+ mice have significantly increased trabecular bone volume, consistent with Clcn7F318L acting as a dominant negative mutation. Clcn7F318L/F318L and Clcn7F318L/G213R mice die by 1month of age and resemble Clcn7 knockout mice, which indicate that p.F318L mutant protein is non-functional and p.F318L and p.G213R mutant proteins do not complement one another. Since it has been reported that treatment with interferon gamma (IFN-G) improves bone properties in Clcn7G213R/+ mice, we treated Clcn7F318L/+ mice with IFN-G and observed a decrease in osteoclast number and mineral apposition rate, but no overall improvement in bone properties. Our results suggest that the benefits of IFN-G therapy in patients with Albers-Schonberg disease may be mutation-specific.
- Published
- 2017
- Full Text
- View/download PDF